Anjani Kumar, CIO of Strides, is bringing his vast experience to managing the day-to-day operations at Strides in a dynamic way

Post pandemic pharmaceutical companies are continuing to strive towards innovative new treatments that help people live longer and healthier lives. These therapies are developed, manufactured, marketed and distributed around the world by pharmaceutical companies every day. The pharmaceutical industry has greatly contributed to the increase in life expectancy for men and women across the world.

Strides is one such global pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world's largest manufacturers of soft gelatin capsules. With world-class manufacturing facilities, an innovative R&D hub in Bangalore and a robust commercial platform to market products globally, Strides has earned a reputation for building and scaling profitable businesses in a short span of time. Strides has a global manufacturing footprint with eight manufacturing facilities spread across four continents, including five US FDA approved facilities and two facilities for the rest of world markets . The Company has a dedicated R&D facility in India with global filing capabilities and a strong footprint across 100 countries.

Manufacturing Wide Range of Niche and Technically Complex Pharmaceutical Products

Pharma Generics: The core generic pharma business of Strides is led by IP-driven product licensing and marketing and distribution partnerships across the globe. The company has leveraged its expertise in niche, difficult-to-develop and manufactures products to emerge as a preferred finished dosage player. Strides has created an exhaustive pipeline of generics across varied formats and domains including oral dosage forms and topicals. They are one among the leading players worldwide in soft gel capsules. Strides’ domain strategy of developing a comprehensive product portfolio in complex therapeutic segments has attracted marquee partnerships in Regulated markets such as US, Europe, Australia, Canada and S. Africa. The company has also increased its data and compliance governance mechanisms and used them effectively for continuous improvements. The risk management process has been enhanced by bringing newer areas or domains into the risk management process, so to address the concerns where needed systematically.

Branded Generics: The company is aiming to be a highly regarded player known for marketing high-quality, locally relevant generic products. To support the strategy of local relevance and affordable pricing, the products are typically supplied out of a regional manufacturing hub as they have a local facility in Africa. The generics are branded so that doctors and patients can recognize and recollect quality products from the Strides stable. Its business activities in this African continent are driven by the philosophy of “In Africa for Africa” which Strides bolstered with the acquisition of a WHO-approved facility under Universal Corporations in Kenya. Plans are underway to enter other regions with business localization strategies.

Research & Development: Strides is led and driven by its expertise in Research and Development, visible through its success in creating niche and differentiated products portfolio. Its global formulation R&D center at Bangalore drives high value product delivery via latest technology platforms. Strides R&D is imbibed with continuous learning and innovation and is actively engaged in the development of a wide range of dosage forms with special emphasis on novel drug delivery systems for solid orals (modified release tablets and capsules) and soft gelatin capsules for both Regulated and Emerging markets. Its product selection for development is mainly focused on niche products characterized by complex formulations across diverse therapeutic segments. With over 200 plus scientists, the R&D team offers solutions across the entire product development value chain including strategic sourcing, IP management, formulation development, analytical method development and validation, technology transfer, bio-equivalence, toxicological studies, packaging development and global regulatory submissions.

The Leader behind Strides’ Success

Anjani Kumar serves as the Chief Information Officer of Strides. He has over 20 years of experience with exposure to numerous industries including, Pharmaceutical, Services, Telecom, Automobile, and Logistics. He has been associated with several Fortune 500 organizations like IBM, Nissan, Cognizant, and has worked as a consultant with Pharmaceutical companies like Pfizer and Sun Pharma (Erstwhile Ranbaxy). His expertise includes IT strategy, Corporate IT, Consulting, and Digital Transformation.

Anjani is a Post Graduate in Marketing & Management from Kelly Business School, Indiana University (USA) and B.E., in Mechanical Engineering, REC/NIT (National Institute of Technology) Rourkela.

“In the challenging and competitive pharmaceutical environment, our business is driven by a strong commitment to quality and to operating with the highest standards of ethics and integrity.”